| Proposed Ticker: PRGN | 777 Old Saw Mill River Road | |
| Exchange: NASDAQ-National Market | Tarrytown, New York 10591 | |
| Industry: Manufacturing | (914) 789-2800 |
| All share information is proposed | ||||
| Type of Shares: | Common Shares | Filing Date: | 10/7/96 | |
| U.S. Shares Filed: | 2,000,000 | Filing Range: | $11.00 - $13.00 | |
| Non-U.S. Shares Filed: | 0 | Offering Amount: | $24,000,000 | |
| Primary Shares: | 2,000,000 | Expenses: | $750,000 | |
| Secondary Shares: | 0 | Shs Out After: | 8,554,553 | |
| Manager | Tier | Phone |
| Oppenheimer & Company, Inc. | Lead Manager | (212) 667-7402 |
| Vector Securities International, Inc. | Co-manager | (708) 940-1970 |
| Auditor: Coopers & Lybrand | |||||
| Audited Income | Latest Unaudited Income | Prior Unaudited Income | Balance Sheet | ||
| 12/31/95 | 6/30/96 | 6/30/95 | 6/30/96 | ||
| Revenue: | $0.82 | $0.31 | $0.35 | Assets: | $4.15 |
| Net Income: | -$4.50 | -$2.09 | -$2.04 | Liabilities: | $0.63 |
| EPS: | -$0.74 | -$0.34 | Equity: | $3.52 | |
Note: Dollar amounts are in U.S. millions; Audited figures expressed as full year, unaudited figures are partial year | |||||
| Business Description |
| The company is a biopharmaceutical company focusing on the development and commercialization of innovative products for the treatment and prevention of cancer and viral diseases. The company applies its immunology expertise to develop biopharmaceuticals that induce an immune response or that mimic natural immunities in order to fight cancers, such as melanoma, and viral diseases, such as immunodeficiency virus ("HIV") infection. |
| Use of Proceeds |
| The proceeds from the proposed offering will be used for general corporate purposes. |
©1996 IPO Data Systems, Inc. - All rights reserved.